Skip to main content
Journal cover image

Triple-Negative Breast Cancer in Older Patients: Does SLNB Guide Therapy?

Publication ,  Journal Article
Record, SM; Thomas, SM; Dalton, J; van den Bruele, AB; Chiba, A; DiLalla, G; DiNome, ML; Rosenberger, LH; Woriax, HE; Hwang, ES; Plichta, JK
Published in: Ann Surg Oncol
August 28, 2024

BACKGROUND: Older breast cancer patients represent a heterogeneous population. Studies demonstrate that sentinel lymph node biopsy (SLNB) omission may be appropriate in some clinical scenarios, yet patients with triple-negative breast cancer (TNBC) are often excluded from these studies. This study evaluated differences in treatment and survival for older patients with TNBC based on SLNB receipt and result. METHODS: Patients 70 years old or older with a diagnosis of cT1-2/cN0/M0 TNBC (2010-2019) who underwent surgery were selected from the National Cancer Database. Logistic regression estimated the association of SLNB with therapy, and Cox proportional hazards models estimated the association of SLNB with overall survival (OS) after adjustment for select factors. RESULTS: Of the 15,167 patients included in the study (median age, 77 years), 13.02% did not undergo SLNB, 5.14% had pN1 disease, 0.12% had pN2 disease, and 0.01% had pN3 disease. Most of the patients (83.9%) underwent surgery first, and 16.1% received neoadjuvant chemotherapy. Of those who underwent surgery first and SLNB, 6.2% had pN+ disease. Receipt of SLNB was associated with a higher likelihood of chemotherapy (odds ratio [OR] 1.85; 95% confidence interval [CI] 1.55-2.21), regardless of pN status. Compared with those who did not undergo a SLNB, a negative SLNB was significantly associated with lower mortality (hazard ratio [HR] 0.68; 95% CI 0.63-0.75), although there was no difference for a positive SLNB (HR 1.14; 95% CI 0.98-1.34). The patients receiving chemotherapy first showed no difference in survival based on SLNB receipt or result (p = 0.23). CONCLUSIONS: Most older patients with TNBC do not have nodal involvement and do not receive chemotherapy. The receipt and results of SLNB may be associated with outcomes for some who undergo surgery first, but not for those who receive neoadjuvant chemotherapy.

Duke Scholars

Published In

Ann Surg Oncol

DOI

EISSN

1534-4681

Publication Date

August 28, 2024

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Record, S. M., Thomas, S. M., Dalton, J., van den Bruele, A. B., Chiba, A., DiLalla, G., … Plichta, J. K. (2024). Triple-Negative Breast Cancer in Older Patients: Does SLNB Guide Therapy? Ann Surg Oncol. https://doi.org/10.1245/s10434-024-16106-x
Record, Sydney M., Samantha M. Thomas, Juliet Dalton, Astrid Botty van den Bruele, Akiko Chiba, Gayle DiLalla, Maggie L. DiNome, et al. “Triple-Negative Breast Cancer in Older Patients: Does SLNB Guide Therapy?Ann Surg Oncol, August 28, 2024. https://doi.org/10.1245/s10434-024-16106-x.
Record SM, Thomas SM, Dalton J, van den Bruele AB, Chiba A, DiLalla G, et al. Triple-Negative Breast Cancer in Older Patients: Does SLNB Guide Therapy? Ann Surg Oncol. 2024 Aug 28;
Record, Sydney M., et al. “Triple-Negative Breast Cancer in Older Patients: Does SLNB Guide Therapy?Ann Surg Oncol, Aug. 2024. Pubmed, doi:10.1245/s10434-024-16106-x.
Record SM, Thomas SM, Dalton J, van den Bruele AB, Chiba A, DiLalla G, DiNome ML, Rosenberger LH, Woriax HE, Hwang ES, Plichta JK. Triple-Negative Breast Cancer in Older Patients: Does SLNB Guide Therapy? Ann Surg Oncol. 2024 Aug 28;
Journal cover image

Published In

Ann Surg Oncol

DOI

EISSN

1534-4681

Publication Date

August 28, 2024

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis